All In Biotech

Drug Trial Radar · NCT07417670

Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease

COMPARATIVE STUDY TO EVALUATE SATISFACTION WITH THE USE OF ORODISPERSIBLE MEMANTINE TABLETS VERSUS CONVENTIONAL TABLETS IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER'S DISEASE: A PHASE IV, RANDOMIZED, OPEN-LABEL STUDY.

Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

105

Actual

Start

Oct 4, 2024

Primary completion

Aug 12, 2025

Study completion Aug 18, 2025

Sponsor

Lead sponsor
Carnot LaboratoriesIndustry
Sponsor type
Industry
First posted
Feb 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to evaluate satisfaction with the use of orodispersible Memantine (OD) versus conventional Memantine tablets (MTb) using the validate SATMED-Q in patients with moderate to severe Alzheimer's disease. Due to the neurocognitive impairment associated with these stages of the disease, treatment satisfaction will be assessed indirectly through the primary caregiver. The main questions this study seeks to answer are: * Is caregiver satisfaction higher with OD (Sinolvir®) compared with MTb? * What adverse events or side effects occur in patients receiving memantine in either pharmaceutical form? Researchers will compare OD (Sinolvir®) and MTb to identify differences in caregiver satisfaction and to describe the adverse events reported. Satisfaction will be evaluated across the six domains of the SATMED-Q questionnaire, and results will be summarized by domain and by pharmaceutical dosage form. All adverse events reported during the study will be documented. Participants will receive Sinolvir®(OD) or Eutebrol® (MTb) daily, according to dosing regimens determined by the treating physicians based on the approved prescribing information. The duration of participation will be two months. After two months of treatment, eligible primary caregivers will complete the SATMED-Q questionnaire. Caregivers will be invited to participate at Visit 1 and will complete the satisfaction questionnaire at Visit 2, which will be conducted between days 60 and 70 after Visit 1.

Conditions

  • Alzheimer Disease

Interventions

  • MemantineDrug

    orodispersible memantine administered according to a dose titration schedule.

  • Memantine Oral TabletDrug

    Conventional memantine tablets administered according to a dose titration schedule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Caregiver treatment satisfaction assessed by the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q)Time frame: Between Day 71 and Day 80 after treatment initiation.

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Ángeles del Pedregal

    Mexico City, Mexico

  • Private Practice

    Saltillo, Coahuila, Mexico

  • Private Geriatrics Practice

    Guadalajara, Jalisco, Mexico

  • Private Practice

    Monterrey, Nuevo León, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.